NasdaqCM:MYOS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has MYOS RENS Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYOS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.9%

MYOS

-1.2%

US Personal Products

-0.7%

US Market


1 Year Return

-27.1%

MYOS

-6.2%

US Personal Products

5.3%

US Market

Return vs Industry: MYOS underperformed the US Personal Products industry which returned -6.1% over the past year.

Return vs Market: MYOS underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

MYOSIndustryMarket
7 Day-13.9%-1.2%-0.7%
30 Day36.2%0.2%4.6%
90 Day19.7%14.0%14.0%
1 Year-27.1%-27.1%-5.1%-6.2%7.6%5.3%
3 Year-33.7%-33.7%40.0%33.3%34.9%26.1%
5 Year-60.5%-60.5%36.1%24.9%62.3%44.7%

Price Volatility Vs. Market

How volatile is MYOS RENS Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MYOS RENS Technology undervalued compared to its fair value and its price relative to the market?

5.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MYOS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MYOS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MYOS is unprofitable, so we can't compare its PE Ratio to the US Personal Products industry average.

PE vs Market: MYOS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYOS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYOS is overvalued based on its PB Ratio (5.2x) compared to the US Personal Products industry average (2.6x).


Next Steps

Future Growth

How is MYOS RENS Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

34.6%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MYOS RENS Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has MYOS RENS Technology performed over the past 5 years?

10.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYOS is currently unprofitable.

Growing Profit Margin: MYOS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYOS is unprofitable, but has reduced losses over the past 5 years at a rate of 10% per year.

Accelerating Growth: Unable to compare MYOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYOS is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (17.5%).


Return on Equity

High ROE: MYOS has a negative Return on Equity (-158.72%), as it is currently unprofitable.


Next Steps

Financial Health

How is MYOS RENS Technology's financial position?


Financial Position Analysis

Short Term Liabilities: MYOS's short term assets ($2.4M) exceed its short term liabilities ($831.0K).

Long Term Liabilities: MYOS's short term assets ($2.4M) exceed its long term liabilities ($146.0K).


Debt to Equity History and Analysis

Debt Level: MYOS's debt to equity ratio (24.7%) is considered satisfactory.

Reducing Debt: MYOS's debt to equity ratio has increased from 0.2% to 24.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYOS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MYOS has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.7% each year.


Next Steps

Dividend

What is MYOS RENS Technology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYOS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Joe Mannello (62yo)

2.92yrs

Tenure

US$83,356

Compensation

Mr. Joseph Mannello, also Known as Joe, has been the Chief Executive Officer of MYOS RENS Technology Inc. since August 24, 2017 and served as its Interim Chief Executive Officer from September 1, 2016 to A ...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD83.36K) is below average for companies of similar size in the US market ($USD612.38K).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Mannello
CEO & Director2.92yrsUS$83.36k12.58% $1.7m
Ren Ren
Global Chairman4.33yrsUS$14.69k0.16% $22.5k
Joseph DiPietro
Controller3.83yrsno datano data
Magshoud Dariani
Chief Technology Officerno datano datano data
Kris Ohrenick
Head of Marketing2.5yrsno datano data
Dante Carnevale
Chief Strategist0.92yrno datano data

2.9yrs

Average Tenure

Experienced Management: MYOS's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joseph Mannello
CEO & Director2.92yrsUS$83.36k12.58% $1.7m
Ren Ren
Global Chairman4.33yrsUS$14.69k0.16% $22.5k
Victor Mandel
Independent Director3.92yrsUS$50.00k1.09% $149.3k
Robert Hariri
Independent Chairman of Board & Chairman of the Scientific Advisory Board8.25yrsUS$4.00k2.59% $353.9k
Christopher Pechock
Independent Director6.42yrsUS$55.00k3.53% $482.7k
Christopher Dewey
Independent Director0.92yrUS$8.00k2.98% $407.9k
Louis Aronne
Independent Director & Member of Scientific Advisory Board9yrsUS$36.00k0.73% $100.1k
Caroline Apovian
Member of Scientific Advisory Board7.42yrsno datano data
Neilank Jha
Member of Scientific Advisory Board8.58yrsno datano data
Eric Zaltas
Independent Director1.58yrsUS$20.00k0.15% $20.5k
Andrew Ponte
Director0.58yrUS$4.00k0.88% $120.9k

4.6yrs

Average Tenure

58yo

Average Age

Experienced Board: MYOS's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.3%.


Top Shareholders

Company Information

MYOS RENS Technology Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MYOS RENS Technology Inc.
  • Ticker: MYOS
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$13.677m
  • Shares outstanding: 11.03m
  • Website: https://www.myosrens.com

Number of Employees


Location

  • MYOS RENS Technology Inc.
  • 45 Horsehill Road
  • Suite 106
  • Cedar Knolls
  • New Jersey
  • 7927
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYOSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2008
73MDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2008

Biography

MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance. The company primarily focuses on developing Fortetropin for the therapeutic markets, including the treatment of sarcopenia, cachexia, anorexia, obesity, and muscular disorders. Its products include Qurr line of products to support muscle well-being and fitness; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Formula line of products for pets. The company sells its products through direct-to-consumer e-commerce platform. It has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; Rutgers University for the discovery of compounds and products that improve muscle health and performance; Weill Cornell Medical College to study the efficacy of Fortetropin in preventing weight and muscle loss associated with cancer; and McMaster University to study impact of Fortetropin on muscle disuse atrophy in young men. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/14 00:06
End of Day Share Price2020/07/13 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.